House Health and Government Operations Committee
March 12, 2009
House Bill 1155-Prescription Confidentiality Act
BIO opposes House Bill 1155 relating to restrictions on disclosure of prescriber-identifiable prescription data. If passed, this bill would have the unintended consequences of negatively impacting patient safety, access to new innovative therapies, and efforts to research and develop biologic medicines.
BIO is a national trade organization, based in Washington, D.C., representing more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. In Maryland we work closely with MdBIO of teh Tech Council of Maryland (TCM), Maryland's largest technology trade association which brings its 500 plus members access to technology industry leaders in Maryland promoting the technology industry to create an environment where technology companies can collaborate, grow and succeed.
Patient care and safety will be at risk. The Food and Drug Administration (FDA) has promulgated regulations that either require or encourage pharmaceutical manufacturers to make direct contact with prescribing physicians under specific circumstances. If manufacturers are no longer able to access prescriber-identifiable prescribing information, patient care and safety will be at risk.